Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
Type:
Application
Filed:
July 6, 2011
Publication date:
July 11, 2013
Applicant:
NOVARTIS AG
Inventors:
Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
Type:
Application
Filed:
February 21, 2013
Publication date:
July 11, 2013
Inventors:
John T. Schiller, Diana V. Pastrana, Richard B.S. Roden, Ratish Gambhira, Douglas R. Lowy
Abstract: Provided herein are compositions and methods for inhibiting viral infection of a host cell. The methods comprise contacting the the host cell with an effective amount of one or more polypeptides having a disintegrin domain. The polypeptide can be CN, VCN or modified ADAM-derived polypeptide (MAP), or a fusion protein comprising a CN, VCN or MAP.
Type:
Application
Filed:
November 12, 2012
Publication date:
July 11, 2013
Applicants:
WESTERN UNIVERSITY OF HEALTH SCIENCES, UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
University of Southern California, Western University of Health Sciences
Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
Type:
Application
Filed:
June 7, 2011
Publication date:
July 11, 2013
Applicant:
NOVARTIS AG
Inventors:
Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
Abstract: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and other diseases.
Abstract: The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.
Type:
Grant
Filed:
October 27, 2006
Date of Patent:
July 9, 2013
Assignee:
Medical and Biological Laboratories Co., Ltd.
Abstract: A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox and anthrax.
Abstract: The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.
Type:
Grant
Filed:
February 22, 2010
Date of Patent:
July 2, 2013
Assignees:
U.S. Army Medical Research and Material Command, Zalicus, Inc.
Inventors:
Lisa M. Johansen, Joseph Lehár, Benjamin G. Hoffstrom, Gene G. Olinger, Andrea R. Stossel
Abstract: The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
July 2, 2013
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Vicky Fachinger, Knut Elbers, Marion Kixmoeller
Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes a sequence from a high titer influenza virus isolate.
Abstract: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.
Type:
Grant
Filed:
January 12, 2011
Date of Patent:
June 25, 2013
Assignee:
The United States of America, as Represented by the Secretary of the Department of Health and Human Services
Inventors:
Dennis M. Klinman, Mayda Gursel, Ihsan Gursel
Abstract: Provided is a fusion protein, which comprises human papillomavirus E7 antigen, virus capsid protein and molecular chaperone. Also provided is a macromolecule with immunogenicity aggregated by the fusion proteins. The particle morphology of the macromolecule is different from that of the virus-like particle. The macromolecule can be used for treatment of human papillomavirus relating diseases.
Type:
Grant
Filed:
June 18, 2008
Date of Patent:
June 25, 2013
Assignees:
Shanghai Zerun-Ankegens Biopharmaceutical Company, Ltd., Yunxu CAO
Abstract: The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections.
Abstract: An isolated influenza B virus which has reduced sensitivity to one or more neuraminidase (NA) inhibitors, wherein the reduced sensitivity to one or more NA inhibitors is associated with a residue in NA other than Ile at position 222, a residue in NA other than Ser at a position 250, or a residue in NA other than Gly at position 402, as well as methods to detect such a virus or determine agents that inhibit the infection or replication of such as virus, are provided.
Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg.
Abstract: The invention is directed to methods of screening immunogenic viral like particles and related immunogenic compositions and diagnostic techniques. In one embodiment, the invention provides methods of screening immunogenic viral like particles containing peptides corresponding to epitope regions of a wide variety of pathogens, including viruses, bacteria, parasites, and microbes. Non-infectious antigens and allergens of interest can also be screened as described herein. Immunization, therapeutic and diagnostic applications are also described for the compositions and methods according to the invention. In another embodiment, the invention provides novel methods of identifying a cryptic neutralizing epitope and related vaccines, constructs, and libraries. In some embodiments, these methods use high-throughput formats that are facilitated by in silica or in vitro steps.
Type:
Application
Filed:
October 26, 2012
Publication date:
June 13, 2013
Inventors:
Brian L. Hjelle, David S. Peabody, Bryce Chackerian
Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
Type:
Application
Filed:
October 7, 2011
Publication date:
June 13, 2013
Inventors:
Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.
Abstract: The invention relates to the discovery that the addition of aromatic carboxylate ions inhibit protein instability caused by aromatic preservatives. Thus, the invention relates to compositions, (preferably aqueous compositions, comprising a protein, an aromatic preservative and aromatic carboxylate ions. The proteins remain stable and suitable for storage at ambient temperatures or lower, even in aqueous form. Preferably, the aqueous composition comprises a protein, a phenolic preservative and benzoate ions, wherein the pH of the composition is at least 1 unit greater than the pKa of benzoic acid. The invention also provides methods of reducing protein degradation by aromatic preservatives in an aqueous formulation of a protein susceptible to such degradation, comprising the step of adding aromatic carboxylate ions to the formulation wherein the formulation is maintained at a pH that is at least 1 unit greater than the pKa of the corresponding aromatic carboxylic acid.
Abstract: A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral immunogenic viral protein. The chimeric viral particle is free of RV E1 protein-encoding gene. A virus packaging cell that generates the chimeric viral particle comprising a RV fusion gene and an isolated expression vector comprising a RV fusion gene linked in translation frame to a promoter are also disclosed.
Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
Type:
Grant
Filed:
August 23, 2011
Date of Patent:
June 11, 2013
Assignee:
Theraclone Sciences, Inc.
Inventors:
Andres Grandea, III, Gordon King, Thomas Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle
Abstract: The present invention relates to uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
Type:
Grant
Filed:
December 17, 2010
Date of Patent:
June 11, 2013
Assignee:
Novartis AG
Inventors:
Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
Abstract: The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.
Type:
Grant
Filed:
September 21, 2011
Date of Patent:
June 11, 2013
Assignees:
Institut Pasteur, Institut National de la Santéde la Recherche Médicale, Centre National de la Recherche Scientifique
Inventors:
Pierre Charneau, Véronique Zennou, Hüseyin Firat
Abstract: The invention relates to immunogenic compositions useful as HCV vaccines. Provided are HCV mosaic polypeptide and nucleic acid compositions which provide higher levels of T-cell epitope coverage while minimizing the occurrence of unnatural and rare epitopes compared to natural HCV polypeptides and consensus HCV sequences.
Type:
Grant
Filed:
September 29, 2010
Date of Patent:
June 11, 2013
Assignee:
Los Alamos National Security, LLC
Inventors:
Karina Yusim, Bette T. M. Korber, Carla L. Kuiken, William M. Fischer
Abstract: Provided are methods and compositions that can be used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue.
Type:
Application
Filed:
June 24, 2011
Publication date:
June 6, 2013
Applicant:
PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A
Inventors:
Timothy M. Block, Anand Mehta, Pamela Norton
Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.
Type:
Application
Filed:
May 26, 2011
Publication date:
June 6, 2013
Applicant:
VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
Inventors:
Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
Abstract: A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.
Type:
Grant
Filed:
May 1, 2009
Date of Patent:
May 28, 2013
Assignee:
University of Rochester
Inventors:
Benjamin L. Miller, Tim R. Mosmann, Robert C. Rose, Charles R. Mace
Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
Abstract: The present invention provides modified multi-chain and multi-subunit proteins and methods for making them. In some protease embodiments the proteins are modified AB5 toxins in which a compound of interest is attached to the A1 chain.
Type:
Application
Filed:
April 20, 2011
Publication date:
May 16, 2013
Applicant:
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.
Type:
Application
Filed:
April 13, 2011
Publication date:
May 16, 2013
Applicants:
Government of the United States, As Representing By the Secretary of the Army, IRM, LLC
Inventors:
Gillis Otten, Tom Yao-Hsiang Wu, Travis K. Warren, Sina Bavari
Abstract: Use of an ubiquitination pathway-related factor, its agonist or antagonist in the preparation of a composition for regulating FOXP3, IL-2, and/or IFN-? activity, in which the ubiquitination pathway-related factor is selected from: Toll-like receptor, ubiquitin ligase, pro-inflammatory cytokine family receptor, and/or its coding sequence. The new type of regulatory factors can regulate regulatory T cells and immune system by regulating FOXP3, IL-2, and/or IFN-? activity. The regulatory factors and their derivatives can also be used as immunoadjuvant for treating or preventing major diseases (such as, infectious diseases and tumor, etc).
Type:
Application
Filed:
July 11, 2011
Publication date:
May 16, 2013
Applicant:
INSTITUT PASTEUR OF SHANGHAI, CAS
Inventors:
Bin Li, Fang Lin, Zuojia Chen, Zhiyuan Li, Fan Pan
Abstract: Disclosed are improved methods for treating an infectious disease with yeast-based immunotherapy, including viral disease, such as disease resulting from hepatitis virus infection, using a pharmacogenomic and response-guided approach based on IL28B genotype of the individual.
Abstract: The present invention relates to a nucleic acid of the general formula (I): GlXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.
Type:
Application
Filed:
June 8, 2012
Publication date:
May 16, 2013
Applicant:
CureVac GmbH
Inventors:
Ingmar Hoerr, Jochen Probst, Thomas Ketterer, Birgit Scheel
Abstract: A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high cell stimulatory capacity.
Abstract: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.
Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.
Abstract: The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell.
Type:
Application
Filed:
June 30, 2011
Publication date:
May 9, 2013
Applicant:
AEON MEDIX INC.
Inventors:
Yong Song Gho, Su Chul Jang, Yoon Keun Kim, Oh Youn Kim
Abstract: A salmonid alphavirus polypeptide comprising an epitope capable of inducing a virus neutralizing immune response, nucleic acids encoding the polypeptide, a vaccine comprising the polypeptide and a method of producing salmonid alphavirus neutralizing antibodies.
Type:
Grant
Filed:
August 16, 2010
Date of Patent:
May 7, 2013
Assignee:
Intervet International B.V.
Inventors:
Stephane Villoing, Michel Bremont, Coralie Moriette, Monique Le Berre
Abstract: New methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and the use thereof in cancer vaccination are provided. The method includes introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).
Type:
Application
Filed:
August 23, 2012
Publication date:
May 2, 2013
Applicant:
Vrije Universiteit Brussel
Inventors:
Kris Maria Magdalena Thielemans, Aude Bonehill
Abstract: Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such compositions. Methods of modulating the release rate of immunological species from microparticles are also described. These methods comprise varying the ratio of the cationic polysaccharide relative to the biodegradable polymer within the microparticles.
Abstract: The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.
Type:
Application
Filed:
December 15, 2010
Publication date:
April 25, 2013
Applicant:
NOVARTIS AG
Inventors:
David Skibinski, Siddhartha Jain, Manmohan Singh, Derek O'Hagan
Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
Type:
Application
Filed:
December 27, 2012
Publication date:
April 25, 2013
Applicant:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).
Type:
Application
Filed:
May 7, 2012
Publication date:
April 25, 2013
Applicant:
Novartis AG
Inventors:
James SUTTON, Feng Xu, Nicholas Valiante, Jiong Lan
Abstract: Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus.
Type:
Grant
Filed:
May 28, 2010
Date of Patent:
April 23, 2013
Assignees:
Washington University, The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Inventors:
David Wang, Herbert Whiting Virgin, IV, Guoyan Zhao, Stacy Finkbeiner, Jan Vinje, Yan Li, Suxiang Tong
Abstract: The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained.
Type:
Grant
Filed:
April 30, 2008
Date of Patent:
April 23, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Manfred Reiter, Leopold Grillberger, Wolfgang Mundt
Abstract: This disclosure relates to compositions and methods for inducing immune response. Specifically, the disclosure relates to a composition comprising a subunit antigen stabilized by a polysaccharide-containing plant extract, in which the antigen consists of virus-like particles that have enhanced mucosal immuno-genicity as a result of the stabilization.
Type:
Application
Filed:
December 23, 2010
Publication date:
April 18, 2013
Applicant:
Arizona Board of Regents for and on behalf of Arizona State University
Inventors:
Charles J. Arntzen, Melissa Herbst-Kralovetz
Abstract: A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3? portion of the first nucleotide which in the natural content is 100% identical to the 5? portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.
Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or, for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors are either integrative or non-integrative (NI) vectors, dependently upon the purpose of their use. The invention relates to the use of gene transfer vectors for unique or for multiple in vivo administration into a host in need thereof. The field of application of the present application concerns in particular animal treatment or treatment of human being (e.g. prophylactic or therapeutic or symptomatic or curative treatment), gene therapy or vaccination in vivo.
Type:
Grant
Filed:
August 1, 2008
Date of Patent:
April 16, 2013
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique, Theravectys
Inventors:
Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
Type:
Grant
Filed:
September 6, 2011
Date of Patent:
April 9, 2013
Assignee:
Zoetis W LLC
Inventors:
André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec